TACE New Cancer Region Is Not Failure - TACE + Sorafenib Should Be Continued Even After New Cancer - 101967

Spotlight
Video

TACE New Cancer Region Is Not Failure - TACE + Sorafenib Should Be Continued Even After New Cancer

Loading........
Description: Masatoshi Kudo, MD from Kindai University, Japan discusses TACE new cancer region is not failure and TACE + Sorafenib should be continued even after new cancer at the 2018 Gastrointestinal Cancers Symposium.
Shared By : Gastrointestinal-Cancer-Meeting
Posted on : 01/26/18
Added : 10 months ago